

Paolo Bossi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7245433/paolo-bossi-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

268
papers

6,164
citations

41
h-index

70
g-index

297
ext. papers

7,887
ext. citations

4.3
avg, IF

5.57
L-index

#	Paper	IF	Citations
268	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2014 , 120, 1453-61	6.4	669
267	High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5630-6	2.2	531
266	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. <i>Oral Oncology</i> , 2009 , 45, 574-8	4.4	150
265	Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2006 , 12, 6643-51	12.9	133
264	Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019 , 27, 3969-3983	3.9	119
263	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). <i>Oral Oncology</i> , 2009 , 45, 986-90	4.4	111
262	Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E2151-8	4.2	107
261	Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. <i>Supportive Care in Cancer</i> , 2013 , 21, 3191-207	3.9	107
260	Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 74362-74379	3.3	104
259	Smoothed (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. <i>Molecular Oncology</i> , 2015 , 9, 389-97	7.9	103
258	Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , 2018 , 3, e000285	6	98
257	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 147-667		92
256	TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 761-6	2.2	92
255	Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4901-6	2.2	86
254	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. <i>Head and Neck</i> , 2016 , 38, 724-31	4.2	82
253	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012 , 23, 1832-7	10.3	82
252	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i> , 2020 , 126, 4423-4431	6.4	82

251	The role of systemic therapy in the management of sinonasal cancer: A critical review. <i>Cancer Treatment Reviews</i> , 2015 , 41, 836-43	14.4	79
250	Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. <i>Oncotarget</i> , 2015 , 6, 9627-42	3.3	79
249	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 372-84	7	75
248	Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?. <i>Oral Oncology</i> , 2017 , 66, 58-63	4.4	70
247	Sinonasal Malignancies of Anterior Skull Base: Histology-driven Treatment Strategies. <i>Otolaryngologic Clinics of North America</i> , 2016 , 49, 183-200	2	67
246	Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. <i>Cancer Research</i> , 2015 , 75, 1205-15	10.1	63
245	Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019 , 27, 3949-3967	3.9	63
244	Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. <i>Annals of Oncology</i> , 2014 , 25, 462-6	10.3	58
243	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 97, 131-42	7	57
242	The pathogenesis of mucositis: updated perspectives and emerging targets. <i>Supportive Care in Cancer</i> , 2019 , 27, 4023-4033	3.9	57
241	Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide. <i>Annals of Oncology</i> , 2018 , 29, 1718-1726	10.3	56
240	Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 774-7; author reply 777-8	6.7	56
239	Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 396-401	10.2	55
238	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. <i>Clinical Cancer Research</i> , 2016 , 22, 3961-70	12.9	53
237	A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. <i>Annals of Oncology</i> , 2003 , 14, 1327-8	10.3	50
236	Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. <i>Supportive Care in Cancer</i> , 2020 , 28, 4589-4612	3.9	47
235	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 67, 174-182	7.5	46
234	Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 100-6	7	45

233	Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 2596-603	7.5	44
232	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016 , 69, 158-165	7.5	44
231	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 102, 47-54	7	44
230	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. <i>Annals of Oncology</i> , 2012 , 23, 435-41	10.3	42
229	Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. <i>Oral Oncology</i> , 2005 , 41, 890-4	4.4	42
228	Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2018 , 29, iv126-iv142	6.3	41
227	Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019 , 27, 3985-3995	3.9	41
226	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2017 , 28, 2820-2826	10.3	39
225	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 167-82	7	39
224	Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?. <i>Oral Oncology</i> , 2016 , 54, 54-7	4.4	39
223	Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. <i>Annals of Oncology</i> , 2014 , 25, 1628-35	10.3	39
222	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. <i>Supportive Care in Cancer</i> , 2013 , 21, 3243-54	3.9	37
221	Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements. <i>Supportive Care in Cancer</i> , 2019 , 27, 3997-4010	3.9	35
220	Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 774-80	4	33
219	Paranasal sinus cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 45-61	7	32
218	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. <i>Oral Oncology</i> , 2013 , 49, 413-9	4.4	32
217	Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 1053-9	4	32
216	Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2020 , 28, 2473-2484	3.9	29

215	Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2020 , 28, 2449-2456	3.9	29
214	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 959-966	4	28
213	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 191-213	7	28
212	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. <i>Annals of Oncology</i> , 2014 , 25, 694-699	10.3	27
211	Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. <i>Supportive Care in Cancer</i> , 2020 , 28, 2457-2472	3.9	26
210	Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2019 , 27, 4011-4022	3.9	26
209	Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods. <i>Supportive Care in Cancer</i> , 2019 , 27, 3933-3948	3.9	25
208	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. <i>Annals of Oncology</i> , 2011 , 22, 2495-2500	10.3	25
207	Prognostic Nomograms in Oral Squamous Cell Carcinoma: The Negative Impact of Low Neutrophil to Lymphocyte Ratio. <i>Frontiers in Oncology</i> , 2019 , 9, 339	5.3	24
206	Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 137, 84-91	7	24
205	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. <i>Cancer Treatment Reviews</i> , 2018 , 65, 78-86	14.4	24
204	Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention". <i>Oral Oncology</i> , 2015 , 51, 112-8	4.4	23
203	Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. <i>Future Oncology</i> , 2013 , 9, 103-14	3.6	23
202	Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. <i>European Journal of Cancer</i> , 2018 , 97, 7-15	7.5	23
201	Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. <i>Annals of Oncology</i> , 2007 , 18, 601-2	10.3	22
200	Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. <i>Oncotarget</i> , 2017 , 8, 47780-47789	3.3	22
199	Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. <i>Cancer</i> , 2020 , 126, 1888-1894	6.4	21
198	Lenvatinib-induced renal failure: two first-time case reports and review of literature. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 379-385	5.5	21

197	Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). <i>Annals of Oncology</i> , 2018 , 29, 985-991	10.3	21
196	Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. <i>Genes</i> , 2017 , 8,	4.2	21
195	The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. <i>Nutrients</i> , 2021 , 13,	6.7	21
194	Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. <i>Supportive Care in Cancer</i> , 2020 , 28, 2485-2498	3.9	20
193	A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. <i>Annals of Oncology</i> , 2017 , 28, 2547-2551	10.3	20
192	Radiotherapy for unresectable sinonasal cancers: dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy. <i>Radiotherapy and Oncology</i> , 2014 , 113, 260-6	5.3	20
191	A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?. <i>Current Opinion in Oncology</i> , 2006 , 18, 253-7	4.2	20
190	Hope in cancer patients: the relational domain as a crucial factor. <i>Tumori</i> , 2015 , 101, 447-54	1.7	19
189	Pain related to cancer treatments and diagnostic procedures: a no man's land?. <i>Annals of Oncology</i> , 2014 , 25, 1097-106	10.3	19
188	Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 1886-93	10.3	19
187	Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. <i>Supportive Care in Cancer</i> , 2014 , 22, 1889-96	3.9	18
186	Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E1521 ⁴⁷		18
185	Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. <i>Cancer Biology and Therapy</i> , 2014 , 15, 678-82	4.6	17
184	Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. <i>Oral Oncology</i> , 2005 , 41, 97-8	4.4	17
183	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. <i>Oral Oncology</i> , 2018 , 86, 266-272	4.4	17
182	Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma. <i>Theranostics</i> , 2021 , 11, 2987-2999	12.1	17
181	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. <i>Supportive Care in Cancer</i> , 2020 , 28, 5059-5073	3.9	16
180	Palifermin in prevention of head and neck cancer radiation-induced mucositis: not yet a definitive word on safety and efficacy profile. <i>Journal of Clinical Oncology</i> , 2012 , 30, 564-5; 565-567	2.2	16

179	Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. <i>Annals of Oncology</i> , 2008 , 19 Suppl 7, vii200-3	10.3	16
178	Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2019 , 27, 142-150	2	16
177	A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy. <i>International Journal of Medical Informatics</i> , 2019 , 129, 404-412	5.3	15
176	Fatigue, a major still underestimated issue. <i>Current Opinion in Oncology</i> , 2018 , 30, 219-225	4.2	15
175	Head and neck tumors other than squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2004 , 16, 236-41	4.2	15
174	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. <i>Cancers</i> , 2020 , 12,	6.6	15
173	Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	15
172	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. <i>Oral Oncology</i> , 2017 , 69, 33-37	4.4	14
171	The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2016 , 17, 53	5.4	14
170	Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. <i>Oral Oncology</i> , 2014 , 50, 884-7	4.4	14
169	Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1): A review. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 143, 67-75	7	13
168	Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. <i>European Journal of Cancer</i> , 2019 , 115, 4-12	7.5	13
167	The point of pain in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 138, 51-59	7	13
166	Multikinase inhibitors in thyroid cancer. <i>European Journal of Cancer</i> , 2010 , 46, 1012-8	7.5	13
165	Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. <i>Head and Neck</i> , 2013 , 35, 1471-4	4.2	13
164	Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma. <i>Clinical Oncology</i> , 2003 , 15, 451-60	2.8	13
163	Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1909-1915	6.1	13
162	Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. <i>Radiologia Medica</i> , 2019 , 124, 414-421	6.5	13

161	The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review. <i>Head and Neck</i> , 2019 , 41, 2410-2429	4.2	12
160	Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. <i>Otolaryngology - Head and Neck Surgery</i> , 2019 , 161, 635-642	5.5	12
159	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	12
158	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. <i>Head and Neck</i> , 2019 , 41, 3670-3676	4.2	12
157	Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 106, 320-328	4	12
156	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. <i>Supportive Care in Cancer</i> , 2016 , 24, 4057-74	3.9	12
155	Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. <i>Oral Oncology</i> , 2018 , 82, 144-151	4.4	11
154	Investigational drugs for head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 797-819	9	11
153	Prevalence of Fatigue in Head and Neck Cancer Survivors. <i>Annals of Otolaryngology and Laryngology</i> , 2019 , 128, 413-419	2.1	10
152	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. <i>Laryngoscope</i> , 2020 , 130, 857-865	3.6	10
151	MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients. <i>Supportive Care in Cancer</i> , 2021 , 29, 3539-3562	3.9	10
150	Preemptive treatment with Xonrid [®] , a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study. <i>Supportive Care in Cancer</i> , 2017 , 25, 1787-1795	3.9	9
149	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	9
148	Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 1217-1221	4	9
147	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2019 , 123, 138-145	7.5	9
146	The 8th TNM classification for oral squamous cell carcinoma: What is gained, what is lost, and what is missing. <i>Oral Oncology</i> , 2020 , 111, 104937	4.4	9
145	Malignant tumors of the maxillary sinus: Prognostic impact of neurovascular invasion in a series of 138 patients. <i>Oral Oncology</i> , 2020 , 106, 104672	4.4	9
144	Sinonasal cancer encroaching the orbit: Ablation or preservation?. <i>Oral Oncology</i> , 2021 , 114, 105185	4.4	9

143	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. <i>European Journal of Cancer</i> , 2020 , 136, 35-42	7.5	8
142	Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience. <i>Targeted Oncology</i> , 2018 , 13, 253-256	5	8
141	Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse. <i>Pain Medicine</i> , 2014 , 15, 758-61	2.8	8
140	Value and Quality of Care in Head and Neck Oncology. <i>Current Oncology Reports</i> , 2020 , 22, 92	6.3	8
139	Pretreatment DWI with Histogram Analysis of the ADC in Predicting the Outcome of Advanced Oropharyngeal Cancer with Known Human Papillomavirus Status Treated with Chemoradiation. <i>American Journal of Neuroradiology</i> , 2020 , 41, 1473-1479	4.4	8
138	Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma. <i>Oral Oncology</i> , 2021 , 115, 105213	4.4	8
137	Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. <i>Value in Health</i> , 2017 , 20, 799-808	3.3	7
136	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. <i>Oral Oncology</i> , 2019 , 90, 94-101	4.4	7
135	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. <i>European Journal of Cancer</i> , 2018 , 93, 89-98	7.5	7
134	Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, e226-8	4.5	7
133	Advances in the changing patterns of aetiology of head and neck cancers. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2006 , 14, 95-9	2	7
132	Management of sinonasal adenocarcinomas with anterior skull base extension. <i>Journal of Neuro-Oncology</i> , 2020 , 150, 405-417	4.8	7
131	Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting. <i>Journal of Alternative and Complementary Medicine</i> , 2016 , 22, 486-8	2.4	7
130	The use of fentanyl in pain management in head and neck cancer patients: a narrative review. <i>British Journal of Pain</i> , 2018 , 12, 155-162	2.1	7
129	Quality Assessment in Supportive Care in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 926	5.3	6
128	Italian version of the M.D. Anderson Symptom Inventory--Head and Neck Module: linguistic validation. <i>Supportive Care in Cancer</i> , 2015 , 23, 3465-72	3.9	6
127	An Environment for Guideline-based Decision Support Systems for Outpatients Monitoring. <i>Methods of Information in Medicine</i> , 2017 , 56, 283-293	1.5	6
126	The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 116, 82-88	7	6

125	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2015 , 44, 734-45	3.3	6
124	Emerging tyrosine kinase inhibitors for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 445-59	3.7	6
123	Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (−) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6020-6020	2.2	6
122	Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aerodigestive tract (NCT02860936).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6086-6086	2.2	6
121	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. <i>European Journal of Cancer</i> , 2021 , 159, 194-204	7.5	6
120	Is pain part of a systemic syndrome in head and neck cancer?. <i>Supportive Care in Cancer</i> , 2020 , 28, 451-459	3.9	6
119	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. <i>Cells</i> , 2020 , 9,	7.9	6
118	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. <i>Cancers</i> , 2021 , 13,	6.6	6
117	Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. <i>Future Oncology</i> , 2019 , 15, 2543-2553	3.6	6
116	Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. <i>Head and Neck</i> , 2018 , 40, 2648-2656	4.2	6
115	Managing older patients with head and neck cancer: The non-surgical curative approach. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 411-417	3.6	6
114	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100468	2.2	6
113	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021 , 157, 250-258	7.5	6
112	The Case Volume Issue in Head and Neck Oncology. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 65	5.4	5
111	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 435-443	5.9	5
110	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. <i>Dysphagia</i> , 2019 , 34, 52-62	3.7	5
109	Gastrointestinal toxicities from targeted therapies: measurement, duration and impact. <i>Current Opinion in Supportive and Palliative Care</i> , 2015 , 9, 163-7	2.6	5
108	Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7757-8; author reply 7758-9	2.2	5

107	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.. <i>European Journal of Cancer</i> , 2021 ,	7.5	5
106	Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9543-9543	2.2	5
105	Sinonasal cancers treatments: state of the art. <i>Current Opinion in Oncology</i> , 2021 , 33, 196-205	4.2	5
104	Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets. <i>Cancers</i> , 2021 , 13,	6.6	5
103	Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E1009-13	4.2	5
102	Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2019 , 41, 1895-1902	4.2	5
101	Toward Personalized Cancer Care for Elderly Head and Neck Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 965-966	4	4
100	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019 , 46, 507-514	1.6	4
99	Respiratory illness and air pollution from the steel industry: the case of Piquil de Baixo, Brazil (Preliminary report). <i>Multidisciplinary Respiratory Medicine</i> , 2016 , 11, 41	3	4
98	NICSO: Network Italiano Cure di Supporto in Oncologia--Italian Network for Supportive Care in Oncology. <i>Supportive Care in Cancer</i> , 2015 , 23, 11-2	3.9	4
97	How many therapeutic options are there for recurrent or metastatic salivary duct carcinoma?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 672; author reply 672-673	2.2	4
96	Biological agents in head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1643-50	3.5	4
95	Activity of afatinib administered in a window pre-operative study in squamous cell carcinoma of the head and neck (SCCHN) : EORTC-90111.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6049-6049	2.2	4
94	RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?. <i>Oncotarget</i> , 2017 , 8, 96184-96189	3.3	4
93	Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 518110	5.3	4
92	Relevance of apparent diffusion coefficient features for a radiomics-based prediction of response to induction chemotherapy in sinonasal cancer. <i>NMR in Biomedicine</i> , 2020 , e4265	4.4	3
91	Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review. <i>Future Oncology</i> , 2014 , 10, 2111-20	3.6	3
90	Biological agents in head and neck cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 10, x45-8	10.3	3

89	The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts.. <i>Cancers</i> , 2022 , 14,	6.6	3
88	Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. <i>Drugs in Context</i> , 2019 , 8, 212611	5.2	3
87	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920977002	5.4	3
86	A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 2479-2487	4.9	3
85	The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures. <i>Frontiers in Oncology</i> , 2020 , 10, 1574	5.3	3
84	The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis. <i>Supportive Care in Cancer</i> , 2021 , 29, 5701-5709	3.9	3
83	M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy + systemic therapy - A study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Oral Oncology</i> , 2021 , 115, 105189	4.4	3
82	Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence. <i>Cancers</i> , 2021 , 13,	6.6	3
81	Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy. <i>Tumori</i> , 2020 , 106, 39-46	1.7	3
80	Defining the needs of patients with recurrent and/or metastatic head and neck cancer: An expert opinion. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103200	7	3
79	Vitamin D Supplementation and Cancer Mortality: Narrative Review of Observational Studies and Clinical Trials. <i>Nutrients</i> , 2021 , 13,	6.7	3
78	Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. <i>Oncologist</i> , 2020 , 25, e946-e954	5.7	2
77	Precision medicine in rare tumors and the need for multicenter trials and international collaboratives: Sinonasal cancer as paradigm. <i>Oral Oncology</i> , 2020 , 109, 104737	4.4	2
76	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. <i>Disease Markers</i> , 2017 , 2017, 6870614	3.2	2
75	Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. <i>Tumori</i> , 2018 , 104, 213-220	1.7	2
74	Nausea and vomiting during the first 3 intercycle periods in chemo-naive cancer patients receiving moderately/highly emetogenic therapy. <i>Tumori</i> , 2015 , 101, 692-6	1.7	2
73	Folate in head and neck squamous cell cancer chemoprevention: purposely left out?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3463; author reply 3463-4	2.2	2
72	Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6027-6027	2.2	2

71	Clinical prognostic factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immune checkpoints therapies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e17530-e17530	2.2	2
70	Treatment Options for Recurrent Anterior Skull Base Tumors. <i>Advances in Oto-Rhino-Laryngology</i> , 2020 , 84, 231-245	1.7	2
69	Oral potentially malignant disorders: new insights for future treatment. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2021 , 29, 138-142	2	2
68	The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation. <i>Oral Oncology</i> , 2021 , 114, 105128	4.4	2
67	Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 162, 103345	7	2
66	Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies. <i>Cancers</i> , 2021 , 13,	6.6	2
65	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. <i>Oral Oncology</i> , 2016 , 58, e4-5	4.4	2
64	The impact of the COVID-19 outbreak on supportive care for oral mucositis: current concepts and practice. <i>Supportive Care in Cancer</i> , 2021 , 29, 2255-2258	3.9	2
63	Difficulties in conducting pure academic research, obstacles in data collection and quality of informations: The example of the INTERCEPTOR study. <i>Oral Oncology</i> , 2019 , 97, 99-104	4.4	1
62	Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer. <i>Head and Neck</i> , 2019 , 41, 908-914	4.2	1
61	May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?. <i>Oral Oncology</i> , 2019 , 94, 121-122	4.4	1
60	PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. <i>Oncology</i> , 2019 , 97, 112-118	3.6	1
59	Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. <i>Future Oncology</i> , 2020 , 16, 1091-1100	3.6	1
58	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 187-204	4.1	1
57	Comment on Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer. <i>British Journal of Cancer</i> , 2018 , 118, e5	8.7	1
56	Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. <i>Clinical Therapeutics</i> , 2019 , 41, 2517-2528.e28	3.5	1
55	Comments on "postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure" by Chan and Coll. <i>Oral Oncology</i> , 2013 , 49, e38	4.4	1
54	TP53 mutations in head and neck cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 1194; author reply 1195	59.2	1

53	Cisplatin and fluorouracil concurrent to radiotherapy in nasopharyngeal cancer: is the schedule compatible?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 377; author reply 377-8	2.2	1
52	Treatment-associated mortality in head and neck cancer receiving chemotherapy and radiation: Meta-analysis of published trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6062-6062	2.2	1
51	Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS6625-TPS6625	2.2	1
50	Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6029-6029	2.2	1
49	Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives.. <i>Frontiers in Oncology</i> , 2021 , 11, 727027	5.3	1
48	Ambrosio Borsano: un exponente de la escuela de ingenierĀ militar de MilĀ al servicio de la MonarquĀ HispĀnica (1633-1661). <i>Hispania - Revista Espanola De Historia</i> , 2017 , 77, 673	0.1	1
47	The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer. <i>Advances in Oto-Rhino-Laryngology</i> , 2020 , 84, 78-86	1.7	1
46	Immunonutrition in head and neck cancer patients undergoing chemoradiotherapy: an alternative approach for overcoming potential bias. <i>American Journal of Clinical Nutrition</i> , 2021 , 113, 1053-1054	7	1
45	Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients. <i>Acta Oncologica</i> , 2021 , 60, 1192-1200	3.2	1
44	Regional disease in head and neck cutaneous squamous cell carcinoma: the role of primary tumor characteristics and number of nodal metastases. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021 , 1	3.5	1
43	Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report. <i>Tumori</i> , 2016 , 102,	1.7	1
42	Psychometric properties of the Italian version of the Speech Handicap Index. <i>Disability and Rehabilitation</i> , 2021 , 43, 1307-1312	2.4	1
41	Peripherally or centrally inserted central catheters: what is the best vascular access device for cancer patients?. <i>Supportive Care in Cancer</i> , 2021 , 29, 2803-2806	3.9	1
40	In Reply to Fakhry et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 670-671	4	1
39	Patient selection for immunotherapy in head and neck cancer. <i>Lancet Oncology, The</i> , 2021 , 22, e290	21.7	1
38	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
37	Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study.. <i>BMC Cancer</i> , 2022 , 22, 243	4.8	1
36	Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression?. <i>Head and Neck</i> , 2019 , 41, 3733-3735	4.2	0

35	Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group.. <i>Frontiers in Oncology</i> , 2022 , 12, 730785	5.3	○
34	Baseline prognostic factors affecting survival in recurrent and/or metastatic salivary gland adenoid cystic carcinoma.. <i>Oral Oncology</i> , 2022 , 126, 105764	4.4	○
33	Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6029-6029	2.2	○
32	Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations. <i>Dermatology Practical and Conceptual</i> , 2021 , 11, e20211705	1.5	○
31	Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic. <i>Frontiers in Oncology</i> , 2021 , 11, 707346	5.3	○
30	Future Perspectives in the Management of Tumors of the Anterior Skull Base. <i>Advances in Oto-Rhino-Laryngology</i> , 2020 , 84, 246-250	1.7	○
29	A monocentric, open-label randomized standard-of-care controlled study of XONRID [®] , a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients. <i>Radiation Oncology</i> , 2020 , 15, 193	4.2	○
28	Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial. <i>BMC Cancer</i> , 2021 , 21, 561	4.8	○
27	Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment. <i>Oral Oncology</i> , 2021 , 116, 105138	4.4	○
26	A European survey on the practice of nutritional interventions in head-neck cancer patients undergoing curative treatment with radio(chemo)therapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021 , 1	3.5	○
25	Prognostic value of H-index in patients surgically treated for squamous cell carcinoma of the larynx. <i>Laryngoscope Investigative Otolaryngology</i> , 2021 , 6, 729-737	2.8	○
24	The efficacy of immunonutrition in improving tolerance to chemoradiotherapy in patients with head and neck cancer, receiving nutritional counseling: study protocol of a randomized, open-label, parallel group, bicentric pilot study. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211025872	5.4	○
23	New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Vaccines</i> , 2022 , 10, 885	5.3	○
22	Comment on Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base. <i>British Journal of Cancer</i> , 2015 , 113, 1638-9	8.7	
21	Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis", by Rades et coll. <i>Oral Oncology</i> , 2010 , 46, 888; author reply 889-90	4.4	
20	Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas?. <i>Oral Oncology</i> , 2005 , 41, 219-221		
19	A nationwide survey among emergency physicians and oncologists to improve the management of immune checkpoint inhibitors toxicity.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	
18	Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials.. <i>Oral Oncology</i> , 2022 , 126, 105756	4.4	

- 17 AUCtox: A new method to evaluate the safety of anticancer drugs in metastatic prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, 290-290 2.2
- 16 Retrospective analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients.. *Journal of Clinical Oncology*, **2019**, 37, e17537-e17537^{2,2}
- 15 Prognostic role of pre-treatment magnetic resonance imaging (MRI) radiomic analysis in patients with squamous cell carcinoma of the head and neck (SCCHN).. *Journal of Clinical Oncology*, **2020**, 38, 6553-6553^{2,2}
- 14 Detecting characteristics of nodal invasion in advanced squamocellular oral cavity cancer through a gene expression profile on primary tumor.. *Journal of Clinical Oncology*, **2015**, 33, e17069-e17069 2.2
- 13 Upregulation of RAS pathway to predict the risk of distant metastases in HPV + oropharynx cancer.. *Journal of Clinical Oncology*, **2015**, 33, e17073-e17073 2.2
- 12 Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area.. *Journal of Clinical Oncology*, **2015**, 33, e17054-e17054^{2,2}
- 11 Meta-analysis: Risk of congestive heart failure (CHF) in selected targeted agents.. *Journal of Clinical Oncology*, **2015**, 33, 64-64 2.2
- 10 Individual patient data meta-analysis of the IMPACT of treatment site on the outcome of head and neck cancer patients treated within 6 randomized trials.. *Journal of Clinical Oncology*, **2016**, 34, 6022-6022^{2,2}
- 9 Carcinoma del rinofaringe **2011**, 293-307
- 8 Carcinomi dei seni paranasali e delle fosse nasali **2011**, 371-390
- 7 Malignant salivary gland tumours in families with breast cancer susceptibility. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 479, 221-226 5.1
- 6 What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations. *Cancer Management and Research*, **2021**, 13, 5203-5210 3.6
- 5 Optimal Supportive Measures during Primary Treatment **2021**, 221-230
- 4 New and Promising Targeted Therapies in First and Second-Line Settings **2021**, 277-296
- 3 Clinical and Histological Prognostic Factors of Recurrence and Malignant Transformation in a Large Series of Oral Potentially Malignant Disorders.. *Frontiers in Oncology*, **2022**, 12, 886404 5.3
- 2 The Role of Systemic Therapy and Targeted Approaches for the Treatment of Sinonasal Malignancies **2022**, 195-204
- 1 Confounding factors in the assessment of oral mucositis in head and neck cancer. *Supportive Care in Cancer*, 3.9